EVM
CNCR

Eaton Vance Management’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Eaton Vance Management’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-100
Closed – – 2819
2021
Q3 		$0 Buy
+100
New +$3.02K ﹤0.01% 2122

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

Eaton Vance Management's CNCR Position: Q4 2021 in Review

Eaton Vance Management sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2021, closing a stake of 100 shares.

Eaton Vance Management first reported a position in CNCR in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 25 funds tracked by Wall St. Rank hold CNCR as of Q4 2021.

  • Eaton Vance Management reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q4 2021 after selling out during the quarter.
  • Eaton Vance Management sold 100 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q4 2021.
  • Eaton Vance Management first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q3 2021 and held it in 1 quarter.
  • Eaton Vance Management's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $0 in Q3 2021.
  • 25 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2021.

Based on Eaton Vance Management's 13F filing for Q4 2021, filed 14 Feb 2022.